期刊
NEUROBIOLOGY OF DISEASE
卷 110, 期 -, 页码 29-36出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2017.10.014
关键词
Adenosine receptors; Alzheimer's disease; Amyloid plaques; Antagonist; Astrocytes; Behavior; Inhibition; Istradefylline; Memory; Therapy
资金
- NIH [K99AG048222, P30NS065780]
- S.D. Bechtel, Jr. Foundation
- MetLife Foundation
- Dolby Family
- National Center for Research Resources [RR18928]
- Alan Kaganov Scholarship [P50AG023501]
Adenosine A(2A) receptors are putative therapeutic targets for neurological disorders. The adenosine A(2A) receptor antagonist istradefylline is approved in Japan for Parkinson's disease and is being tested in clinical trials for this condition elsewhere. A(2A) receptors on neurons and astrocytes may contribute to Alzheimer's disease (AD) by impairing memory. However, it is not known whether istradefylline enhances cognitive function in aging animals with AD-like amyloid plaque pathology. Here, we show that elevated levels of A beta, C-terminal fragments of the amyloid precursor protein (APP), or amyloid plaques, but not overexpression of APP per se, increase astrocytic A(2A) receptor levels in the hippocampus and neocortex of aging mice. Moreover, in amyloid plaque bearing mice, low-dose istradefylline treatment enhanced spatial memory and habituation, supporting the conclusion that, within a well-defined dose range, A(2A) receptor blockers might help counteract memory problems in patients with Alzheimer's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据